Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) EBITDA (2016 - 2022)

Historic EBITDA for Aptevo Therapeutics (APVO) over the last 8 years, with Q4 2022 value amounting to -$7.7 million.

  • Aptevo Therapeutics' EBITDA fell 9019.8% to -$7.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$28.6 million, marking a year-over-year decrease of 3383.64%. This contributed to the annual value of -$18.6 million for FY2023, which is 3488.36% up from last year.
  • According to the latest figures from Q4 2022, Aptevo Therapeutics' EBITDA is -$7.7 million, which was down 9019.8% from -$7.8 million recorded in Q3 2022.
  • Over the past 5 years, Aptevo Therapeutics' EBITDA peaked at -$4.0 million during Q4 2021, and registered a low of -$13.5 million during Q1 2018.
  • Moreover, its 5-year median value for EBITDA was -$7.6 million (2022), whereas its average is -$8.5 million.
  • As far as peak fluctuations go, Aptevo Therapeutics' EBITDA soared by 4721.62% in 2020, and later crashed by 9019.8% in 2022.
  • Aptevo Therapeutics' EBITDA (Quarter) stood at -$12.1 million in 2018, then increased by 21.09% to -$9.6 million in 2019, then increased by 28.75% to -$6.8 million in 2020, then skyrocketed by 40.75% to -$4.0 million in 2021, then crashed by 90.2% to -$7.7 million in 2022.
  • Its last three reported values are -$7.7 million in Q4 2022, -$7.8 million for Q3 2022, and -$7.6 million during Q2 2022.